Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 26 Sep 2021
On new recommendation for treatment of COVID-19 patients: WHO calls for equitable access to casirivimab and imdevimab for COVID-19
24 September 2021 - The World Health Organization welcomes the addition of another therapeutic to the world’s arsenal against COVID-19, ...
Posted by Michael Wonder on 26 Sep 2021
Australia secures supply of drug that treats arthritis and Covid
25 September 2021 - Health Minister Greg Hunt has secured an extra supply of a rheumatoid arthritis drug to treat critically ...
Posted by Michael Wonder on 26 Sep 2021
FDA tweaks biosimilar application review program
25 September 2021 - The FDA has struggled during the COVID-19 pandemic to conduct timely reviews of biosimilar approval applications. ...
Posted by Michael Wonder on 26 Sep 2021
Manitoba family calling for province to cover life-changing drug
26 September 2021 - A new drug called Trikafta could be a life-changing treatment option for people living with cystic ...
Posted by Michael Wonder on 26 Sep 2021
Pharmacy Guild plan to halve PBS general patient charge for prescription medicine prices
26 September 2021 - The Pharmacy Guild has declared war on discount chains like Chemist Warehouse. ...
Posted by Michael Wonder on 25 Sep 2021
MSAC publishes agenda for upcoming PASC meeting
24 September 2021 - The MSAC Secretariat has published a list of the applications scheduled to be considered at the next ...
Posted by Michael Wonder on 25 Sep 2021
CARISMA Therapeutics announces U.S. FDA grants fast track designation to CT-0508 for the treatment of patients with solid tumours
22 September 2021 - CARISMA Therapeutics announced today that that the U.S. FDA has granted fast track designation to CT-0508, ...
Posted by Michael Wonder on 25 Sep 2021
FDA approves Repatha (evolocumab) in paediatric patients age 10 and older with heterozygous familial hypercholesterolaemia
24 August 2021 - Approval based on HAUSER RCT demonstrating a significant reduction in low-density lipoprotein cholesterol. ...
Posted by Michael Wonder on 25 Sep 2021
Doctors too keen to operate, say experts
25 September 2021 - Doctors are routinely over-diagnosing and over-treating conditions that do not require medical intervention, sometimes carrying out ...
Posted by Michael Wonder on 25 Sep 2021
Vertex's supplement to a new drug submission for Kalydeco (ivacaftor) for patients with cystic fibrosis between the ages of 4 months and 18 years with the R117H mutation in the CFTR gene accepted for priority review by Health Canada
22 September 2021 - Vertex Pharmaceuticals today announced its supplement to a new drug submission for Kalydeco (ivacaftor) has been ...
Posted by Michael Wonder on 25 Sep 2021
Ontario providing access to life changing treatment for cystic fibrosis patients
24 September 2021 - Ontario is now providing coverage for Trikafta, the latest and most effective treatment option for cystic fibrosis ...
Posted by Michael Wonder on 25 Sep 2021
Pfizer and OPKO announce extension of U.S. FDA review of biologics license application of somatrogon for paediatric growth hormone deficiency
24 September 2021 - 4, 2021 - Pfizer and OPKO Health announced today that the U.S. FDA has extended the review ...
Posted by Michael Wonder on 24 Sep 2021
ATAGI update following weekly COVID-19 meeting (22 September 2021)
24 September 2021 - An update from the Australian Technical Advisory Group on Immunisation following their weekly meeting on 22 September ...
Posted by Michael Wonder on 24 Sep 2021
EU drugs regulator to decide on Pfizer vaccine booster in early October
23 September 2021 - The EMA aims to decide in early October whether to endorse a third dose of the ...
Posted by Michael Wonder on 24 Sep 2021
Pear Therapeutics announces additional coverage decisions and formulary adoption of its prescription digital therapeutics
23 September 2021 - More than 30 organizations now provide access to Pear’s prescription digital therapeutics by either listing on formulary, ...